LR 5%, MPL 19%, and TN 13%); leukocytosis was not significant ( p = 0.8); multivariable analysis confirmed significance of wild-type ASXL1 / RUNX1 / EZH2 genotype ( p = 0.03), age >60 years ( p = 0.05) and absence of extreme thrombocytosis ( p = 0.05), while driver mutation profile was relegated to borderline significance ( p = 0.09).
A similar analysis restricted to arterial events occurring before or after diagnosis revealed a near-significant association for driver mutation profile ( p = 0.2; JAK2 22%, CALR 14%, MPL 22%, and TN 19%) and significant associations for the absence of ASXL1 ( p = 0.02) or RUNX1 ( p = 0.05) mutations; a similar analysis for venous events marked driver mutation profile ( p = 0.03; JAK2 21%, CALR 10%, MPL 15% and TN 13%) and absence of SRSF2 ( p = 0.03) or EZH2 ( p = 0.02) mutations as being significant.